ICC Says Darfur War Crimes Probe Reaches Breakthrough in Sudan Investigation 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Trump Administration Hands Over Key Evidence in Minnesota Immigration Shooting Investigations 
Goldman Sees Foreign Investors Driving India Stock Market Recovery 
Iraq PM Visits Washington as U.S. Oil, Gas Deals Take Center Stage 
Japanese Yen Holds Steady as Intervention Hopes Grow Ahead of U.S. CPI Data 
Oil Prices Surge as U.S.-Iran Conflict Escalates and Strait of Hormuz Risks Grow 
Asian Stocks Slide as Oil Surge, U.S.-Iran Tensions and Fed Rate Bets Weigh on Markets 
Deutsche Bank Sees Global Capital Shifts Reshaping Long-Term U.S. Dollar Outlook 
Amy Coney Barrett Faces Conservative Backlash After Key Supreme Court Rulings Against Trump 
China Trade Surplus Hits $125.6 Billion as June Exports, Imports Smash Forecasts 
US Egg Producers Settle Price Manipulation Probe, Agree to Pay $3.3 Million and Donate 53 Million Eggs 
EU Weighs New Trade Restrictions on Israeli West Bank Settlements 
Texas Man Charged After Fatal Tesla Full Self-Driving Crash in Katy 
Trump, Canada Reach Gordie Howe Bridge Deal Ahead of July 27 Opening 
DOJ Seeks Dismissal of Fraud Charges Against Gautam Adani in U.S. Court 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
